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Direct reprogramming of an adult cell into another differentiated lineage—such as fibroblasts into neurons, 
cardiomyocytes, or blood cells—without passage through an undifferentiated pluripotent stage is a new area 
of research that has recently emerged alongside stem cell technology and induced pluripotent stem cell repro-
gramming; indeed, this avenue of investigation has begun to play a central role in basic biological research 
and regenerative medicine. Even though the field seems new, its origins go back to the 1980s when it was 
demonstrated that differentiated adult cells can be converted into another cell lineage through the overexpres-
sion of transcription factors, establishing mature cell plasticity. Here, we retrace transdifferentiation experi-
ments from the discovery of master control genes to recent in vivo reprogramming of one somatic cell into 
another from the perspective of possible applications for the development of new therapeutic approaches for 
human diseases. 
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Relevance of Reprogramming Adult Cells Into  
Another Phenotype
Understanding the stability of the differentiated state 
and the possibility of altering this state is interesting both 
from a basic biological perspective and for its potential 
to generate new research tools and cell sources for ther-
apy. Final cell types of these reprogramming processes, 
progenitors and mature cells, may be directly used in 
applications such as cell replacement therapies.
Among the many innovative ideas proposed to achieve 
this goal, a particularly interesting one involves not only 
the complete reprogramming of fully committed adult 
cells into a pluripotent state but also generation of tar-
get adult cells by direct conversion of one cell type to 
another. From this perspective, here we evaluate the lit-
erature and consider the experimental evidence of direct 
lineage changes of adult cells (Table 1). 
INTRODUCTION
Cell differentiation is a process by which cells become 
more specialized, acquiring new identities. Biologists 
often describe this process of development as proceeding 
from an undifferentiated (pluripotent) cell to a terminally 
differentiated cell that forms part of an adult tissue or 
organ. Different body parts arise in embryonic develop-
ment because different, specific combinations of genes 
encoding transcription factors become activated (153). 
States of terminal cell differentiation are often considered 
to be fixed and irreversible, but in some cases, the balance 
of transcription factors can change and cells can inter-
convert (151,154). It is now known that the stable states 
of differentiated cells are controlled by dynamic mecha-
nisms that can be perturbed under specific conditions, 
and an adult cell therefore can be reprogrammed, altering 
its pattern of gene expression—and thus its fate—to that 
typical of another cell type (136,177). 
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Table 1. Summary of Different Transdifferentiation Procedures Presented in the Literature
Final Cell Type Starting Cell Type Transcription Factors Species Efficiency (%) Author Year
Myoblasts Fibroblast-like 10T1/2 MyoD Mouse 50 Davis (34) 1987
Myoblasts Fibroblasts, pigment, 
nerve, fat, liver cells
MyoD Mouse, rat, 
chicken, 
human
50 Weintraub 
(184)
1989
Myoblasts Fibroblasts, chondrob-
lasts, smooth muscle, 
retinal pigmented 
epithelial cells
MyoD Mouse, rat, 
chicken, 
human
— Choi (30) 1990
Eosinophils and 
thromboblasts
Myelomonocytes GATA-1 Chicken — Kulessa (93) 1995
Macrophages B-Cells CEBPα- and CEBPβ
CEBPα-PU.1
Mouse 60
92
Xie (193) 2004
Macrophages B-Cells CEBPα- and CEBPβ Mouse 100 Bussman (22) 2009
Macrophages
Dendritic-like cells
Pre-T-cells CEBPβ
CEBPa-
PU.1
Mouse 60
—
Laiosa (96) 2006
Macrophages Fibroblast NIH 3T3 CEBPα-
PU.1
Mouse 35–40 Feng (44) 2008
Monocytes Neural stem cells PU.1 Mouse — Forsberg (46) 2010
Cardiomyocytes Posterior and medial 
mesoderm, amnion
Gata4, Tbx5, Baf60c Mouse — Takeuchi (168) 2009
Cardiomyocytes Postnatal cardiac or 
dermal fibroblasts
Gata4, Tbx5, Mef2c Mouse 20–30 Ieda (77) 2010
Cardiomyocytes Fibroblasts Oct4, Sox2, Klf4 and 
c-Myc
Mouse — Efe (38) 2011
Neurons Astroglial cells Neurogenin2, Mash1 Mouse 85 Berninger (13) 2007
GABAergic neurons
Glutamatergic neurons
Astroglia Dlx2
Neurogenin2
Mouse — Heinrich (66) 2010
Neurons Embryonic and postnatal 
fibroblast
Ascl1, Brn2, Myt1l Mouse 1.8–7.7 Vierbuchen 
(176)
2010
Neurons Fibroblasts Ascl1, Brn2, Myt1l 
and NeuroD1
Human 21 ± 9 Pang (128) 2011
Neurons Fibroblasts miR-9/9, miR-124, 
NeuroD2, Ascl1 
and Myt1l
Human 80 Yoo (195) 2011
Dopaminergic neurons Fibroblasts Mash1, Nurr1 and 
Lmx1a
Mouse and 
human
85 ± 4 Caiazzo (23) 2011
Dopaminergic neurons Fibroblasts Ascl1, Pitx3, Lmx1a, 
Nurr1, Foxa2, and 
EN1)
Mouse — Kim (85) 2011
Neurons 
Dopaminergic neurons
Embryonic and postnatal 
fibroblasts
Ascl1, Brn2 and 
Myt1l
Ascl1, Brn2,
Myt1l, Lmx1a and 
FoxA2
Human 16 ± 4.3
10
Pfisterer (132) 2011
Motor neuron Fibroblasts Ascl1, Brn2, Myt1l,
Lhx3, Hb9, Isl1 and 
Ngn2
Ascl1, Brn2, Myt1l,
Lhx3, Hb9, Isl1 and 
Ngn2, NEUROD1
Mouse 
Human
5–10
—
Son (156) 2011
Adipocytes 3T3 fibroblasts PPARg Mouse — Tontonoz (172) 1994
Adipocytes Fibroblasts cell lines C/EBPa Mouse Up to 50 Freytag (47) 1994
Adipocytes Myoblasts PPARg, C/EBPa Mouse 20–30 Hu (73) 1995
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Reprogramming in Nature
Nature offers only rare examples in which cells of 
one type can be converted to another type in a process 
called cellular reprogramming (127). These events have 
been referred to as transdifferentiation or dedifferentia-
tion (153).
Developmental biologist David Tosh has restricted 
the definition of transdifferentiation to irreversible swit- 
ches of one differentiated cell type to another (12,39, 
120,137,146,162). Metaplasia represents one example of 
natural transdifferentiation; it is the replacement in a tis-
sue of one differentiated cell type with another or, more 
generally, transformation of one tissue type into another 
(149,151,152,189). Metaplasias often occur in tissues that 
have been subjected to chronic trauma, damage, infec-
tion, or abnormal chronic stimulation (153). 
Transdetermination is the name given to a form of 
metaplasia that involves transformations between different 
imaginal discs in Drosophila melanogaster. Occasionally, 
the disc will differentiate into a structure appropriate to 
another disc. It is a rare event involving a population of 
cells, and certain changes are more common than others, 
such as wing structures arising from the tissue of a leg 
disc (64). 
Dedifferentiation is a cellular process in which a ter-
minally differentiated and specialized cell reverts to an 
earlier, more embryonic developmental stage or to a sim-
pler unspecialized form. It is often seen in more basal 
life forms such as worms and amphibians and also in 
plants (27,57). 
Important information about lineage reprogramming 
comes from dedifferentiation in regeneration, namely, 
the recreation of an adult structure by reactivation of 
embryonic genes that normally function during organ 
development (27,152). Sometimes dedifferentiation and 
metaplasia result in an aberration of the normal devel-
opment cycle and can have direct consequences. Indeed, 
they can predispose individuals to the development of 
cancer or be considered as the first step in a multistep 
progression to cancer (6,43). 
Reprogramming in the Laboratory 
Scientists have long tried to reproduce natural repro-
gramming in laboratory experiments. This idea has been 
realized using three distinct experimental approaches to 
nuclear reprogramming: nuclear transfer, cell fusion, and 
transcription factor transduction. All of these experimen-
tal approaches have demonstrated that the differentiated 
state is not fixed but is instead actively maintained and 
reversible (17,60,167,194).
Pioneering cloning studies in frogs in 1952 revealed 
that the transfer of nuclei from early blastocysts into 
enucleated oocytes resulted in cloned organisms (18). 
This experiment provided the first conclusive evidence 
that genes are not lost or permanently silenced dur-
ing cell specialization; however, this finding was diffi-
cult to reproduce with donor cells from more specialized 
tissues (194). 
In the 1960s, somatic cell nuclear transfer was achieved 
in which nuclei from differentiated adult cells were repro-
grammed to a totipotent state after injection into enucleated 
eggs (61,70). Using this approach, Wilmut and colleagues 
fused a mammary cell with an enucleated oocyte, and in 
1997, successfully cloned a mammal for the first time, 
Dolly the sheep (190). 
Cell fusion involves melding two or more cell types 
into one cell called a heterokaryon or hybrid (194). 
This fusion allows study of the effect of one genome on 
another, and in this way in the late 1960s, the existence 
of transacting repressors and tumor-suppressor proteins 
was discovered. Several decades ago, it was shown that 
silenced genes can be expressed again in differenti-
ated cells by the fusion of different cell types (14–17). 
This approach provides the tools needed to clarify the 
Table 1. Summary of Different Transdifferentiation Procedures Presented in the Literature (Continued)
Final Cell Type Starting Cell Type Transcription Factors Species Efficiency (%) Author Year
Adipocytes NIH-3T3 fibroblasts SREBP-1 Mouse 15–25 Kim and 
Spiegelman (87)
1996
Adipocytes MC3T3-E1 osteoblasts PPARg, C/EBPa Mouse — Kim (90) 2005
Adipocytes C2c12 myoblast PPARgwt,PPARgmut Mouse — Yu (198) 2006
Adipocytes C2c12 myoblast PRDM16 Mouse — Seale (144) 2008
b-Cells Pancreatic exocrine cells Ngn3, Pdx1, MafA Mouse 20 zhou (206) 2008
Hepatocyte Mouse tail-tip 
fibroblasts
Gata4, Hnf1a and 
Foxa3, and inacti-
vation of p19Arf
Mouse 23 Huang (74) 2011
Hepatocyte Embryonic and adult 
fibroblasts
Hnf4a plus Foxa1, 
Foxa2 or Foxa3
Mouse 0.3 Sekiya (145) 2011
See the text for the definitions of transcription factors.
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regulatory mechanisms, such as DNA demethylation, that 
are required for nuclear reprogramming (194). 
In 2006, Takahashi and Yamanaka described a ground-
breaking work, reproduced and expanded by many other 
groups, showing that expression of key pluripotent tran-
scription factors reprogram adult skin cells to a pluri-
potent state that resembles the embryonic stem cell (ESC) 
(113,129,166,167,186,197). The authors identified four 
key factors that sufficed to induce pluripotency in fibro-
blasts—octamer-binding transcription factor 4 (OCT4), 
sex determining region Y box 2 (SOX2), Krüppel-like 
factor 4 (KLF4), and avian myelocytomatosis viral onco-
gene homolog (c-MYC), or as an alternative group, 
OCT4, SOX2, Homeobox protein NANOG, and cell 
line age 28 protein (LIN 28)—and designated these cells 
“induced pluripotent stem cells” (iPSCs) (36,167). The 
iPSCs meet the original defining criteria for ESCs: they 
give rise to all three germ layers, form teratomas, and 
can form adult chimaeras and generate functional germ 
cells. Moreover, growth at clonal density demonstrated 
their self-renewal capacity (121,129,186). This finding 
opened the path to the possibility of generating patient- 
specific pluripotent cells for disease mechanism studies and 
therapy development. 
In addition to pluripotent reprogramming, other repro-
gramming approaches more directly convert mature 
cells to progenitors or other mature cells without rever-
sion to pluripotent cells. Below, we describe the transdif-
ferentiation process by retracing experiments from the 
discovery of master control genes to in vivo reprogram-
ming of one somatic cell into another and the underlying 
clinical relevance.
MASTER CONTROL GENES
Twenty years ago, Lewis introduced the term “master 
control genes” for the homeotic genes of the Drosophila 
bithorax complex (103) that switches the fate of segments 
between alternative differentiation pathways. This obser-
vation revealed that the activation of only one or a few 
specific genes is responsible for determining differentia-
tion in a specific cell type. Master control genes are either 
the first genes activated in a hierarchy or a transcription 
factor that activates a specific pathway. The expression 
of this group of factors is both necessary and sufficient 
to trigger activation of many other genes, leading to the 
development of a specific tissue or organ. Master control 
genes specify the body plan of animals and humans.
It was demonstrated first in D. melanogaster (50,142) 
that the overexpression of a single master gene in somatic 
cells activates cohorts of genes typical of other somatic 
cell types, leading to important alterations in cell fate 
(194). Indeed, Gehring and colleagues reported that ecto-
pic overexpression of the homeotic Antennapedia gene, 
under the control of a heat-shock gene promoter, results in 
a change in body plan in D. melanogaster larvae, induc-
ing an additional set of legs in the antennal discs (142). In 
the years following this discovery, homeotic mutations in 
Drosophila led to the identification of several master con-
trol genes that specify the body plan, organizing anterior–
posterior polarity, segmental identity, organogenesis, and 
identity of individual cells. 
Subsequently, master genes have also been identified 
in mammals (34). In particular, in mice, Weintraub and 
colleagues induced a phenotypic conversion to the myo-
genic lineage by transfecting into fibroblast or adipoblast 
cell lines a single muscle gene, myogenic differentiation 
antigen (MyoD) (98,124,140,169,184). MyoD (169), a 
member of the basic helix–loop–helix family of myogenic 
regulatory, sequence-specific DNA-binding proteins, is 
a master regulatory gene for skeletal myogenesis and is 
expressed in skeletal muscle (40,125,183). This classical 
experiment is considered one of the most important land-
marks in this field, clearly providing for the first time the 
idea that a single gene can induce cell fate conversion, 
even between distantly related somatic cell lineages. 
Another outstanding example of a master control gene is 
paired box gene 6 (Pax6), one of the most analyzed among 
the Pax genes. Considerable evidence has defined Pax6 as a 
“master control” gene that plays a key role in the develop-
ment of eyes and other sensory organs, certain neural and 
epidermal tissues during neurogenesis, and other homolo-
gous structures, usually derived from ectodermal tissues.
Pax6 encodes a transcription factor that contains a 
paired domain and a homeodomain. It was first cloned in 
mouse (69,178) and in humans (171) and subsequently 
shown to be affected in the mouse mutant Small eye and 
in people with aniridia (50). Pax6 genes from various 
animal phyla can induce ectopic eye development on the 
legs, wings, and antennae of D. melanogaster, indicat-
ing that Pax6 is a master control gene for eye morpho-
genesis and evolution (50). Sometimes a single master 
control gene is not sufficient for reprogramming, but 
as shown by recent work with iPSCs, a group of tran-
scription factors could be required to trigger the repro-
gramming of fibroblasts into pluripotent stem cells 
(84,114,129,166,167,186,197). 
TRANSDIFFERENTIATION
Transdifferentiation is the reprogramming of one spe-
cialized cell type into another, without reversion to pluri-
potent cells. A primary goal of regenerative medicine is to 
convert existing adult cells from one cell type to another 
to provide a source of patient-specific cells. The first step 
is to identify key genes for transdifferentiation. Achieving 
this goal requires gene expression profiling of the target 
cell types for selection of signature factors that play a 
key role in the cells’ determination and/or specification. 
Selected factors will be introduced in vitro or in vivo into 
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other cell types, which then will be reprogrammed into 
the target cells for assessment of the genes’ function in 
direct reprogramming. In vitro cultures allow testing of 
a large number of factors in parallel; on the other hand, 
in vivo systems are more demanding and provide context 
for the cells in their native environment. 
Transdifferentiation in Mesodermal Derivatives
Transdifferentiation in Skeletal Muscle. In 1987, Davis 
and colleagues first identified a myogenic master control 
gene (34). It was known that myogenic, adipogenic, and 
chondrogenic clones can be derived from embryonic 
mouse fibroblasts after treatment with the DNA demeth-
ylating agent 5-azacytidine (170). The relative high effi-
ciency of this conversion suggested that few key genomic 
loci are involved. At present, this reprogramming is attrib-
uted to demethylation of cytosine-phosphate-guanine 
(CpG) island promoters. Based on this evidence, Davis’ 
group screened a myocyte cDNA library, isolating and 
testing a number of cDNA clones specific for myogenic 
cells and muscle tissue (34). They found that one of these 
cDNAs transfected into fibroblast-like 10T1/2 cells was 
sufficient to convert them to stable myoblasts (Fig. 1). 
Davis and colleagues cloned cDNAs into an expression 
vector under the control of the Moloney sarcoma virus 
long terminal repeat (LTR) with a simian virus 40 (SV40) 
poly(A) addition signal (11). Transfected cells were 
selected for G418 (antibiotic) resistance and fixed and 
scored for myosin heavy chain (MHC) expression with an 
alkaline phosphatase-linked immunostaining. About 50% 
of selected colonies were myosin-positive, with multinu-
cleated syncytia, and morphologically indistinguishable 
from myogenic colonies derived by 5-azacytidine treat-
ment of 10T1/2 cells. Furthermore, the team also con-
firmed myogenic conversion in other mouse fibroblast 
cell lines and in adipoblasts (34). In 1988, Tapscott et al. 
recognized that this gene is MyoD (169). 
A few years later, using the same viral vector, the 
same group reproduced the experiments with different 
cell lines and concluded that forced expression of MyoD 
can activate markers indicative of muscle differentiation 
in cell lines from each of the three germ layers (pigment, 
nerve, fat, liver, and fibroblasts) and of several spe-
cies (mouse, rat, chicken, and human) (184). However, 
because chicken cells do not yield stable clones, a MyoD 
encoding an amphotropic retrovirus (LMDSN) was used 
(171), yielding multinucleated myotubes and 50% of 
cells intensely positive for MHC and desmin (184). 
Figure 1. Reprogramming of fibroblasts. Fibroblasts can be converted into several adult cell types based on overexpression of different 
transcription factors. For an explanation of the panels and abbreviations, see the text.
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Based on the same transfection method and with the 
construct donated by Weintraub, in 1990 Choi confirmed 
the conversion by MyoD of dermal fibroblasts, chondro-
blasts, gizzard smooth muscle and retinal pigmented epi-
thelial cells (30). The obtained myotubes presented the 
same characteristics of normal control day-10 embryonic 
breast muscles in terms of elongated morphology, num-
ber of nuclei, density of myofibrils, and the sarcomeric 
localization of antibodies to α-actinin, titin, nebulin, 
α-actin, troponin-I, tropomyosin, major histocompatibil-
ity complex, myosin light chain, myomesin, and desmin 
(30). Intriguingly, these myotubes contracted spontane-
ously. There is, however, an important difference with 
respect to the capacity for replication of myogenic cells 
in primary control cultures and of myogenic cells gener-
ated in MyoD-converted cultures (30). It is likely that the 
overexpression of MyoD limited proliferation capacity 
(34,105), as Davis et al. previously reported (34). 
Muscular dystrophies, including Duchenne muscu-
lar dystrophy (DMD) and Becker’s muscular dystrophy 
(BMD), are genetic, progressive degenerative disorders 
of skeletal muscles, without any effective cure. Cell trans-
plantation of donor muscle satellite cells as a therapeutic 
strategy both in DMD patients and in BMD patients has 
been unsuccessful, mainly because of immune rejection, 
poor survival, and limited diffusion after local intramus-
cular injection (114,134). The use of genetically modi-
fied autologous myogenic cells should avoid most of 
the immune rejection problems, even if immunogenicity 
remains a critical open question. In theory, because iPSCs 
can be generated from a patient’s own somatic cells, 
they will be autologous. However, zhao et al. recently 
reported that mouse iPSCs were rejected with massive 
cluster of differentiation 4 positive (CD4+) T-cell infil-
tration even when the transplantation was performed in 
a syngeneic mouse (204). This important finding sug-
gested that further investigation is needed to confirm 
and understand the immunogenicity. In fact, the reaction 
could be a response against undifferentiated cells that 
form a teratoma, while the immunogenicity of iPSC-
derived differentiated cells has not yet been assessed 
(122). Subtle epigenetic changes, genomic mutation, and/
or other modification occurring during transdifferentia-
tion and prolonged culture of reprogrammed cells could 
have important consequences for immunity response 
and must be experimentally addressed. Both ESCs and 
iPSCs would be expected to develop mutations in their 
genomes during the cultivation process, but if the immu-
nogenicity of such cells is weak, we should be able to 
control the immune responses of the recipient through 
a proportionally reduced immunosuppressant treatment. 
However, the use of ex vivo genetically corrected myo-
genic cells is seriously limited by the number of primary 
myogenic cells that can be isolated and transplanted into 
the patient’s muscles. Therefore, fibroblasts converted 
to myoblasts would represent an alternative, abundant 
source of autologous myogenic cells, avoiding immune 
rejection. In fact, fibroblasts are not affected in their 
growth capacity in dystrophies and can be easily obtained 
from a single biopsy and expanded in vitro without sig-
nificant limitation. The converted myogenic cells could 
then, in theory, be corrected in their defective gene ex 
vivo and reimplanted into the patients. 
Several groups have explored the possibility of using the 
MyoD gene to induce myogenic conversion of nonmuscle, 
primary cells in a quantitatively relevant way (175). In one 
study, primary human and murine fibroblasts from skin, 
muscle, or bone marrow were infected by an E1-deleted 
adenoviral vector carrying a retroviral LTR-promoted 
MyoD cDNA. MyoD-converted cultures were injected 
into regenerating muscle of immunodeficient mice, where 
they gave rise to new muscle fibers, supporting the feasi-
bility of this approach (99). To modulate more precisely 
the fibroblast–myogenic conversion, this group previously 
described the feasibility of using an inducible promoter 
to switch on MyoD on demand (35). The strategy of per-
forming transplantation with myogenic cells converted 
from fibroblasts is hampered by the comparatively lower 
engraftment efficiency relative to that achieved using pri-
mary myogenic cell-derived skeletal muscle cells. 
Modulating the sequential expression of one or more 
muscle master gene transcription factors like Pax3/7, gene 
myogenic factor 5 (Myf-5), and MyoD or others would 
be of interest to achieve a myogenic cell phenotype, like 
mesoangioblasts (165) or CD133+ cells (173), that has a 
more favorable behavior in a cell transplantation setting; 
these cell types may also allow for the possibility of sys-
temic endovascular administration. One futuristic idea is 
to achieve the direct in vivo conversion of fibro-adipose 
tissue that infiltrates dystrophic muscles with a regulat-
able expression of specific myogenic and nonmyogenic 
transcription factors with or without administration of the 
defective gene (like wild-type full-length dystrophin or 
mini-dystrophin) by gene therapy or contemporaneous 
gene correction with other strategies like exon skipping. 
Transdifferentiation in Heart Tissue. Despite a robust 
understanding of the transcriptional regulation of the 
developing heart (126,160), no single master control 
gene like MyoD for skeletal muscle (34) was identified 
as the activator of the cardiac gene program de novo in 
mammalian cells or tissues until 2009. In fact, in that 
year, Takeuchi showed that a group of master con-
trol genes, two cardiac transcription factors, guanine- 
adenine-thymine-adenine (GATA) binding protein 4 
(Gata4) and t-box transcription factor 5 (Tbx5), and a 
cardiac-specific subunit of the polymorphic SWItch/
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Sucrose NonFermentable (Swi/Snf)-like brahma-related 
gene 1 [Brg1]/brahma homologue [Brm]-associated fac-
tor (BAF) chromatin remodeling complexes, Baf60c, 
can directly reprogram mouse mesoderm into beating 
cardiomyocytes (168). Baf60c, a cardiac-enriched BAF 
complex subunit, has important roles in cell-type specifi-
cation and differentiation (97,102,104,150,192), linking 
DNA-binding transcription factors to BAF complexes. 
Gata4, a transcription factor gene expressed in the devel-
oping embryonic heart, is essential for normal cardiac pat-
terning and vascularization (33,71,94,118,135,200,206), 
whereas Tbx5 has been implicated in cardiac morpho-
genesis (21,28). Induction of cardiac differentiation was 
assessed by expression of the early cardiac marker gene 
actin, a cardiac muscle 1 (known as Actc1), gene myo-
sin, light chain 2, regulatory (known as Myl2) messen-
ger RNA, tropomyosin, and cardiac troponin T (cTnT) 
proteins, specific markers of the embryonic heart. 
Cotransfection was performed also in the posterior and 
medial mesoderm, which are normally not fated to car-
diac lineages, and in the amnion, resulting in ectopic 
cTnT and beating tissue induction. Gata4 with Baf60c 
initiated ectopic cardiac gene expression; in particular, 
Baf60c is required to allow Gata4 to bind cardiac genes 
in noncardiac mesoderm. Addition of Tbx5 allowed dif-
ferentiation into contracting cardiomyocytes and repres-
sion of noncardiac mesodermal genes (168).
Recently, Ieda and colleagues examined a total of 14 
key cardiac regulators, and after a systematic process of 
progressive elimination, they defined a minimal com-
bination of three developmental transcription factors, 
Gata4, myocyte enhancer factor 2c (Mef2c), and Tbx5, 
that rapidly and efficiently reprogrammed postnatal car-
diac or dermal fibroblasts directly into differentiated 
 cardiomyocyte-like cells (77) (Fig. 1). To select candidate 
reprogramming factors, they focused on genes that are 
expressed at high levels in cardiomyocytes with respect 
to cardiac fibroblasts and that caused developmental 
defects in cardiac tissue when mutated in mice (77). 
Cells were transduced by retroviruses or lentiviruses. The 
induced cardiomyocytes were similar, even identical, to 
neonatal cardiomyocytes in global gene expression pro-
file and markers of cardiac fibroblasts, suggesting that 
global transcriptional and protein profile reprogramming 
occurred. The authors also demonstrated that fibroblasts 
were epigenetically reprogrammed into cardiomyocytes 
by comparing active and repressive histone modifications 
and DNA methylation in the promoter region of a small 
set of cardiac-specific genes. Gata4 might open chroma-
tin structure in cardiac loci (31), thus allowing binding of 
Mef2c and Tbx5 to their specific target sites and leading 
to full activation of the cardiac program (77). 
Intriguingly, trimethylated H3 on lysine (K)-27 
(H3K27) levels were higher in tail-tip fibroblasts than in 
cardiac fibroblasts, suggesting that fibroblasts from dif-
ferent tissues might have different propensity to specific 
lineage reprogramming. Indeed, cells were electrophysi-
ologically active and could contract spontaneously, with 
a phenotype similar to ventricular cells. Further inves-
tigations are needed to determine whether other types 
of cardiomyocytes, such as cells of the atrium or sinus 
node, can be generated directly from fibroblasts, for 
instance adding different reprogramming factors. The 
authors provided also some insights on the behavior of 
the reprogrammed cardiomyocytes in vivo. They trans-
planted cardiac fibroblasts 1 day after viral transduc-
tion and injected them into nonobese diabetic severe 
combined immunodeficient (NOD-SCID) mouse hearts, 
demonstrating that grafted cells completed their cardiac 
differentiation in vivo. These findings warrant further 
investigation for the development of cell repair strategies 
in cardiac diseases (77). 
A completely different approach was described by 
Efe et al., who obtained from fibroblasts spontaneously 
contracting patches of differentiated cardiomyocytes 
over a period of 11–12 days using four transcription fac-
tors (Oct4, Sox2, Klf4, and c-Myc) (38). After transfec-
tion, fibroblasts were cultured in leukemia inhibitory 
factor-free medium containing 5% fetal bovine serum, 
small molecules that might enhance cardiogenesis, and 
the small-molecule inhibitor of the Janus kinase/signal 
transducer and activator of transcription (JAK-STAT) 
pathway. Given the fact that four iPSC reprogramming 
factors were used to directly reprogram cardiomyocytes 
from mouse iPSCs, this method likely took advantage of 
the rapid mouse iPSC conversion and fast cardiomyocyte 
differentiation from mouse iPSCs. A detailed mechanism 
underlying this method must be carefully dissected and 
confirmed with human fibroblasts (38). 
Overall, these experiments provided evidence that 
the fibroblast-to-cardiac conversion occurred directly, 
without passing through a cardiac progenitor-like state 
or a pluripotent state. This reprogramming potential has 
implications for human health. Heart disease is the lead-
ing cause of adult and childhood mortality and morbidity 
in the western world. These diseases consist of heart fail-
ure, typically the loss of cardiomyocytes, or congenital 
heart malformations, an improper development of cardio-
myocytes during embryogenesis. The heart has little or 
no regenerative capacity after damage; current therapeu-
tic approaches are limited due to the lack of a renewable 
source of cardiomyocytes. The human heart is composed 
of cardiomyocytes, vascular cells, and cardiac fibroblasts. 
The latter comprises over 50% of the whole cells in the 
heart (10,24,155), representing a potential source of beat-
ing cardiomyocytes for regenerative therapy if it was pos-
sible to reprogram them directly. Such a reprogramming 
would have many therapeutic implications; in fact, large 
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amounts of cardiomyocytes can be obtained from a single 
biopsy and could eventually be used for transplantation 
in damaged hearts. A major goal is to introduce defined 
factors into the heart, directly converting the endogenous 
fibroblasts in vivo. 
Transdifferentiation in Immunosystem and Hematopoi- 
etic Cells. Hematopoietic differentiation initiates when 
a multipotent hematopoietic progenitor differentiates to 
form a common lymphoid and a common myeloid pro-
genitor, followed by a process of binary decisions, result-
ing in committed cells of various lineages (1,2,42,115). 
Each lineage exhibits a distinct gene expression pattern 
regulated by a set of several lineage-restricted transcrip-
tion factors that establish new gene expression programs 
during differentiation while suppressing old ones (25,41, 
54,125,147,148). Among these transcription factors, GATA-1 
has emerged as a candidate regulator of hematopoietic 
cell differentiation. GATA-1 was originally identified as 
an erythroid-specific factor involved in globin gene reg-
ulation (93,95) and expressed in megakaryocytes, mast 
cells, and eosinophils (108,109,138,159,208). Using this 
evidence as a starting point, together with the finding 
that GATA-1 is highly expressed in thrombocytic and 
erythroid progenitors and completely downregulated 
during myelomonocytic differentiation (56), Kulessa 
and colleagues investigated the role of GATA-1 in lin-
eage determination by forcing its expression in v-myb 
myeloblastosis viral oncogene homolog-, v-ets erythro-
blastosis virus E26 oncogene homolog (Myb-Ets)-, and 
v-Myc-transformed chicken myelomonocytic cell lines 
(Fig. 2). Cells electroporated with the retroviral expres-
sion vector pneomicin(NEO)-GATA-1 were converted 
into eosinophils and thromboblasts, as indicated by the 
expression of markers specific to eosinophilic cells and 
thrombocytic cells, such as eosinophil-specific cell sur-
face antigen 47 (EOS47) or multipotent hematopoietic 
precursors 21 (MEP21), and by the change in morphology 
and mRNA expression (93). A correlation between the 
GATA-1 expression level and the induced phenotype was 
demonstrated as the suppression of myelomonocytic 
markers in myeloblasts caused by GATA-1 activation (93). 
Figure 2. Transdifferentiation in the immune system. (A) Reprogramming of monocytes into eosinophils through guanine-adenine-
thymine-adenine (GATA) binding protein 1 (Gata-1) overexpression (93); (B) forced expression of cytidine-cytidine-adenosine- 
adenosine-thymidine (CCAAT)/enhancer binding protein (C/EBPa) and purine-rich (PU) box binding protein 1 (PU.1) in fibroblasts 
induces the formation of macrophages (44,193), whereas the overexpression of C/EBPa alone in B-cells and T-cells induces the con-
version into macrophages (22,193); (C) transdifferentiation of pre-T-cells into dendritic cells through the overexpression of PU.1 (96); 
(D) acquisition of monocytes through overexpression of PU.1 in neural stem cells (46).
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GATA-1, therefore, resembles the MyoD family of tran-
scription factors (34). However, Kulessa surmised that 
other transcription factors such as the cytidine-cytidine-
adenosine-adenosine-thymidine (CCAAT)/enhancer bind-
ing protein (C/EBP) may have a role in hematopoietic 
differentiation (93). 
Xie and colleagues confirmed this hypothesis in 2004 
(193). In particular, their study reported that enforced 
expression of C/EBPa and C/EBPβ in differentiated 
B-cells leads to their rapid and efficient reprogram- 
ming into macrophages (193) (Fig. 2). C/EBPa is a basic 
region-leucine zipper (bzip) family transcription factor, 
strictly required for the development of granulocyte and 
macrophage precursors (201–203). In addition, the over- 
expression of this factor induces myelomonocytic differ-
entiation in human multipotent progenitors (78) and in 
committed B-cell precursors (72,193). The related family 
member C/EBPβ is also expressed in myelomonocytic 
cells and eosinophils and can rescue granulocyte forma-
tion in C/EBPa-defective mice (81). Xie’s group used a 
retroviral approach to express the myeloid transcription 
factors C/EBPa and C/EBPβ in primary B-cell precursors 
derived from C57Bl/6J mice bone marrow. Infected cells 
downregulated CD19 and upregulated Mac-1 (CD11b), 
with ~60% of the cells becoming CD19− Mac-1+ after 
4 days (191). Their similarity to macrophages was demon-
strated by morphological changes, as the reprogrammed 
cells were large and contained granules, and by their 
phagocytic capacity (54). 
Bussmann et al. repeated this result with higher effi-
ciency (100%) within 2–3 days using an estradiol- 
inducible form of C/EBPa in the absence of stroma (22). 
In the Xie et al. experiments, gene profiling indicated 
that C/EBPa and β reprogram B-cells into macrophages 
through a series of sequential changes that require endog-
enous purine-rich(PU) box binding protein 1 (PU.1) (193). 
This transcription factor of the Ets family is required for 
the development of myelomonocytic cells (183,185,202), 
dendritic cells, B-cells, and T-cells (4,58,112,143,157) 
and repre-sents another candidate gene with a key role 
for lymphoid and myeloid commitment.
Xie’s group suggested that C/EBP nonresponder cells 
may express low levels of endogenous PU.1 and subse-
quently coinfected these cells with both C/EBPa and 
PU.1 viruses, reaching 92% efficiency (193). Despite the 
fact that each lineage, lymphoid and myeloid, exhibits a 
distinct gene expression, the Xie study reported for the 
first time the transdifferentiation from mature lymphoid 
cells to myeloid cells. 
Laiosa et al. also demonstrated this specific conversion, 
finding that C/EBPa and C/EBPβ induce the formation of 
inflammatory macrophages from pre-T-cells whereas PU.1 
reprograms them into myeloid dendritic-like cells (95) 
(Fig. 2). Pre-T-cells from lck ancestry mice were infected 
with retroviruses containing genes encoding C/EBPa, 
C/EBPβ, and PU.1. The obtained cells were analyzed by 
fluorescence-activated cell sorting: cells induced by 
C/EBPa and C/EBPβ were Mac-1+Gr-1+CD62L+CD11c–
MHCII–F4/80–, a phenotype characteristic of inflamma-
tory macrophages (51); cells generated by PU.1 infection 
were Mac-1+Gr-1–CD62L–CD11c+MHCII+F4/80lo, resem-
bling myeloid dendritic cells (147). Cell morphology also 
confirmed these findings. Approximately 60% of the 
C/EBPa- and C/EBPβ-infected pre-T-cells were repro-
grammed into macrophages that were functional and able 
to internalize opsonized sheep red blood cells. Semiqua n- 
titative RT-PCR showed that at day 9, expression of 
all myeloid genes tested was evident in both C/EBP- 
infec ted samples, whereas expression of all T-cell genes 
tes ted had become undetectable. Furthermore, Notch was 
identified as an important gene, providing a direct link 
between the transcription factor network and extracellular 
signals (96).
All of the studies described so far concerned the con-
version of committed hematopoietic cells into another 
blood cell type that was closely developmentally related, 
probably sharing transcriptional networks and chromatin 
configurations. However, in 2008, Feng and colleagues 
obtained macrophage-like cells from a cell type distantly 
related to blood cells, fibroblast cells (44) (Fig. 2). Based 
on the unexpected finding that PU.1 and C/EBPa upregu-
late Mac-1 expression in fibroblasts (193), Feng’s group 
investigated whether their expression is sufficient to acti-
vate a myeloid program in a fibroblast cell line as well as 
in primary embryonic and adult fibroblasts (44) (Fig. 1).
NIH 3T3 cells were coinfected with PU.1 and C/EBPa 
viruses tagged with green fluorescent protein (GFP) and 
human CD4, respectively. PU.1 or C/EBPa alone induced 
the upregulation of the myelomonocytic marker Mac-1 
and the pan-hematopoietic marker CD45 in 35–40% of 
the infected cells after 5 days, whereas their coexpres-
sion increased the number of Mac-1+ cells to 90%. The 
result was also confirmed in induced primary fibroblasts 
and in cultures prepared from mouse embryos, as well as 
in a skin biopsy of an adult mouse, although with lower 
efficiency. Converted cells more closely resembled a 
macro phage cell line than the original fibroblast cells 
in terms of morphology, phagocytic capacity, and par-
tial inflammatory response. The gene expression profile 
validated that the converted cell lines were macrophage- 
like cells, exhibiting upregulated macrophage-restricted 
genes and downregulated fibroblast-associated genes. 
However, the reprogrammed fibroblasts of Feng et al. 
represented intermediates that required the continuous 
and exogenous expression of PU.1 and C/EBPa to main-
tain a macrophage phenotype (44).
After all of these studies in the hematopoietic field, 
the specific transcription factor PU.1 emerged as crucial. 
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Indeed, recently, Forsberg’s group reported that adult 
neural stem cells can be reprogrammed to monocytes 
at very high efficiency by ectopic expression of the Ets 
transcription factor PU.1 (46) (Fig. 2). Neural stem cells 
were derived from the adult mouse forebrain, cultured 
as neurospheres, and transduced with a lentiviral con-
trol vector containing only GFP or a vector bicistro-
nically expressing hemagglutinin (HA)-tagged PU.1 and 
GFP. High-efficiency reprogrammed neural stem cells 
resembled monocytes in marker profile, morphology, 
and chemotactic response. The reprogramming capac-
ity appears to be unique to neural stem cells; indeed, 
PU.1 is insufficient to efficiently reprogram fibroblasts, 
which are more distantly related mesodermal cells (46). 
Although neural stem cells are even more distantly 
related to the hematopoietic lineage, they are more ame-
nable to reprogramming thanks to their plasticity; they 
express some of the reprogramming factors, such as 
Sox2 and c-Myc (88), at high basal levels, which may 
enhance their ability to modify their fate in response to 
extracellular signals. 
The speed and efficiency with which hematopoietic cells 
can be reprogrammed by C/EBP and PU.1 led to the ques-
tion of whether this plasticity can be relevant in pathologi-
cal conditions, such as leukemia. Some myeloid leukemias 
show immunoglobulin gene rearrangements (116), and 
Hodgkin’s lymphoma cells express some genes specific to 
monocytic and dendritic cells and contain immu noglobulin 
rearrangements and somatic hypermutations (95). 
A recent interesting study from Szabo et al. described 
the direct conversion of human dermal fibroblasts into 
multilineage blood progenitors (164). The latter were 
able to differentiate into cells expressing markers of gran-
ulocytic, monocytic, megakaryocytic, and erythroid lin-
eages. The induction of hematopoietic lineage phenotype 
was promoted by the expression of the pluripotency key 
gene OCT4 in combination with specific culture condi-
tions permissive for hematopoiesis. This result was unex-
pected because OCT4 is a transcription factor regulating 
pluripotency not expressed in the hematopoietic system. 
Indeed, in these specific experimental conditions, OCT4 
did not induce pluripotency but rather promoted a specific 
lineage commitment. Future studies may clarify whether 
Oct4 mimics other hematopoietic Pou domain-containing 
transcription factors, such as Oct1 or Oct2, or may induce 
some partially reprogrammed cells that can subsequently 
be differentiated into blood lineages with appropriate 
environmental signals. Indeed, the authors provided a 
remarkable example of a reasonable basis for autologous 
cell replacement therapies. In fact, they demonstrated 
the in vivo engraftment capacity of obtained multipo-
tent blood progenitors. Reprogrammed cells engrafted 
in all transplanted recipients up to a level of 20% (164). 
Knowledge about master genes involved in hematopoietic 
differentiation may be useful for converting fibroblasts or 
other specific patient cells into hematopoietic cells that 
may be a source for autologous transplantation.
Transdifferentiation in Adipocytes. Adipocyte differen-
tiation is a complex process that involves dramatic changes 
in cell morphology and gene expression regulated mainly 
by a cascade of transcription factors (20). In recent years, 
scientists have identified potential regulators of this pro-
cess. In adipocytes, differentiation appears to be controlled 
by three major factors or groups of factors: C/EBPα, per-
oxisome proliferator-activated receptor (PPAR)γ, and ste-
rol regulatory element-binding protein-1 (SREBP-1). As 
noted, C/EBPs are members of the basic leucine zipper 
transcription factor family (111). Three C/EBP isoforms, 
C/EBPα, C/EBPβ, and C/EBPδ, are expressed at high 
levels during adipocyte differentiation (26); the best char-
acterized, C/EBPa, plays an important role in terminal adi-
pocyte differentiation (106,202,203). PPARγ proteins are 
members of the nuclear hormone receptor superfamily that 
are expressed primarily in adipocytes and play a crucial 
role in the activation of genes involved in very early adipo-
cyte differentiation (7,9,106,158,200). SREBP-1 has been 
identified as a proadipogenic basic helix–loop–helix tran-
scription factor, expressed in particular in the early phase 
of mouse adipocyte differentiation (71,87). 
Tontonoz et al. (172) and Freytag et al. (47) provided 
the first evidence of the C/EBPa and PPARγ key role 
in 1994. Tontonoz et al. expressed PPARγ ectopically 
in fibroblasts 3T3 using the Moloney murine leukemia 
retrovirus (MMLV) (119). Transfected cells, cultured 
under permissive conditions for adipogenesis, differen-
tiated into lipid-containing cells that morphologically 
resembled cultured adipocytes and expressed typical 
adipocyte-linked differentiation genes (Fig. 1). PPARγ 
exerts its adipogenic effects probably through the tran-
scriptional activation of genes required for the adipocyte 
differentiation program or through interaction with other 
proteins like retinoid X receptor (172). 
Freytag’s group transduced the C/EBPa gene into 
mouse fibroblastic cell lines by retroviruses, generating 
adipocyte colonies at variable frequencies (47) (Fig. 1). 
The most efficient result was obtained with NIH 3T3 
cells (>50%). One year later, in 1995, Hu and colleagues 
showed that adipocytes can be obtained from a related but 
highly specialized cell type, myoblasts, by transfection 
with the same two transcription factors used by Tontonoz 
et al. and Freytag et al. (47,73,172).
In 1996, Kim and Spiegelman demonstrated adipo-
cyte reprogramming using another factor, SREBP-1 (86) 
(Fig. 1). Recent studies have reported obtaining adi-
po cytes from osteoblasts and myocytes (198). In fact, 
PPARg acts also as a molecular switch between osteogenic 
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and adipogenic pathways (3,80,101). In differentiation 
medium, ectopic expression of this transcription factor, 
together with C/EBPa, has led to differentiation of osteo-
blasts into adipocytes (89). To generate osteoblastic cells 
(MC3T3-E1) stably overexpressing PPARc2 and/or C/
EBPa, these cells were transduced with a respective ret-
rovirus. Foci of adipocytes arose from day 4 after treat-
ment both with PPARγ and C/EBPa-PPARγ; however, 
the lipid droplet size remained smaller in cells transfected 
with PPARγ compared with the lipid droplets obtained 
with C/EBPa-PPARγ transfection (89). 
As reported above in 1995 (73), myoblasts can be 
converted into adipocytes with retroviral transfection; in 
2006, another group confirmed the result, overexpress-
ing only a plasmid carrying wild-type PPARγ or mutated 
PPARγ (serine 112 was mutated to alanine) in mouse 
myoblast cells (7). Transfected cells expressed adipo-
genic marker genes such as adipocyte fatty acid bind-
ing protein, lipoprotein lipase, and glycerol-3 phosphate 
dehydrogenase and showed increased adipogenic gene 
expression. The ability to transdifferentiate was greater in 
cells with mutated PPARγ than in cells expressing wild-
type PPARγ (194). 
The central role of PPARγ was confirmed by Seale and 
colleagues (144). They showed that the C2C12 myoblast 
cell line and myoblasts isolated from postnatal skeletal 
muscle and transduced with gene PR domain containing 
16 (PRDM16)-expressing retroviruses then transdifferen-
tiated into lipid-filled adipocytes using adipogenic induc-
ers. In the obtained adipocytes, the myotube-specific 
genes such as myoD, myogenin, myogenic regulatory 
factor 4 (mrf4), MHC, and myosin light chain kinase were 
blocked, whereas adipocyte-specific genes, including 
PPARγ and adipocyte protein 2/fatty acid binding protein 
4 (aP2/FABP4), were upregulated. Moreover, PPARγ was 
found in the PRDM16 complex and was demonstrated to 
interact with and be coactivated by PRDM16. PRDM16 
was unable to promote adipogenesis in PPARγ-deficient 
fibroblasts, indicating that PPARγ activation is essential 
(144). All of these studies together demonstrated that 
PPARγ is the master control gene of adipogenic differen-
tiation (8,139,172).
Human lipodystrophies represent a heterogeneous 
group of diseases characterized by generalized or partial 
adipose tissue deficiency (49). They result from either the 
failure of adipocyte development or the immune-mediated 
premature destruction of adipocytes; moreover, the 
remaining mature adipocytes appear to be dysfunctional. 
The immediate consequences of this disorder include 
abnormalities in energy storage, postprandial lipid buff-
ering, and adipokine production. Adipocytes obtained 
through fibroblast transdifferentiation can be useful as a 
source of fat cells that can be grafted into lipodystrophic 
areas. Currently, the fat used for fat transfer is extracted 
from part of the patient’s body and injected into another 
area that requires it. However, it can be difficult to detect 
fat areas in patients, and reprogrammed fibroblasts can 
represent a promising alternative.
Transdifferentiation in Ectodermal Derivatives: Neurons
Several neuronal-specific transcription genes are 
involved in neuronal commitment from stem/precursor cells 
during development and thus can be potential candidate 
genes in transdifferentiation experimental approaches. 
As we mentioned above, Pax6 is one of the master 
genes responsible for neuronal differentiation; indeed, it 
is expressed in radial glia of the developing cortex (50), 
and it is indispensable for cortical neurogenesis from 
these cells (68,182). Moreover, Pax6 plays a crucial role 
in generation of neurons from astroglial stem cells in the 
adult subependymal zone (53,62). Postnatal astroglia can 
be redirected toward neurogenesis by forced expression of 
Pax6 in vitro (68). 
In recent years, many efforts have been made in the field 
of neuronal reprogramming. Berninger and colleagues 
showed that the proneural genes neurogenin-2 (Ngn2) 
and mammalian achaete scute homolog 1 (Mash1) can 
reprogram astroglial cells from early postnatal cerebral 
cortex into neurons (13). These factors were chosen because 
they can drive a glutamatergic versus γ-aminobutyric 
acid (GABA)ergic fate in precursors of the developing 
forebrain (59) as well as in neural stem cells from the 
adult subependymal zone in vitro (13). Postnatal astro- 
glia were transduced using vesicular stomatitis virus G pro-
tein pseudotyped retroviruses containing a Pax6–internal 
ribosomal entry site (IRES)–GFP (63), Ngn2–IRES–
GFP, or achaete-scute complex homolog 1 (Mash1)–
IRES–GFP (13,65). The efficiency of the method was 
~85%. After 12 days, converted cells expressed pro-
teins characteristic of immature neurons, such as class 
III β-tubulin (68), and differentiated into excitable cells 
as demonstrated by electrophysiological characteriza- 
tion. However, astroglia-derived neurons showed no spon-
taneous or evoked synaptic activity, a severe limitation 
toward functional neurogenesis, probably because of a 
delay in the maturation process or an incomplete repro-
gramming. Moreover, given the lack of functional presyn-
aptic output, the neuronal subtype generated could not be 
defined (13). 
A few years after this work, Heinrich et al. tried for 
a stronger and more persistent expression of neurogenic 
fate determinants for a more complete reprogramming 
of astroglia toward synapse-forming neurons (66). The 
LTR-driven MMLV-derived retroviral constructs that 
Berninger’s group had used were expressed only about 
two- to threefold compared to endogenous expression 
(67,68) and were prone to silencing (48). Thus, Ngn2 
or gene distal-less homeobox 2 (Dlx2) were expressed 
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under the control of an internal chicken β-actin promoter 
with a cytomegalovirus enhancer optimized for long-term 
expression over months in the adult mouse brain together 
with DsRed located behind an IRES (201). Postnatal 
cortical astroglia transduced with Ngn2, which directs 
the generation of exclusively excitatory glutamatergic 
neurons in the dorsal telencephalon, differentiated into 
class III β-tubulin-positive, glial fibrillary acidic protein-
negative synapse-forming glutamatergic neurons after 
10 days in culture with high efficiency. The group also 
tested another transcription factor, the homeobox Dlx2, 
which is involved in GABAergic neuron specification in 
the developing ventral telencephalon (131) and in adult 
neurogenesis (19). Forced expression of Dlx2 in post-
natal cortical astroglia gave rise to cells with a neuronal 
identity as revealed by class III β-tubulin or microtubule-
associated protein 2 (MAP2) expression; however, the 
efficacy of neurogenesis was significantly lower than that 
obtained with Ngn2. Patch-clamp recordings revealed 
that Dlx2 induced a GABAergic identity in the repro-
grammed astroglia, even if Dlx2-induced reprogramming 
remained partial in most of the cells. Coexpression of 
Dlx2 and Mash1, a transcription factor located upstream 
of Dlx2 in the interneuron fate specification (133), pro-
duced a higher proportion of transfected neurons exhib-
iting specific interneuronal firing patterns compared 
to Dlx2 alone, indicating that these two factors indeed 
act synergistically. Moreover, the efficiency of repro-
gramming toward a GABAergic neuronal subtype was 
increased, expanding postnatal cortical astroglia under 
neurosphere conditions. Finally, it was demonstrated that 
Ngn2 or Dlx2 overexpression can also be reprogrammed 
into functional neurons from reactive astroglia from adult 
cortex following injury after prior expansion as neuro-
spheres (66).
The direct relationship between the reprogramming 
factors used and the neurotransmitter phenotype is very 
close to the physiological events occurring during the 
development that are likely recapitulated in this process. 
Indeed, the reprogramming occurred without cell division 
as in the vast majority of direct differentiation experiments. 
These studies can open the path to the direct in vivo 
conversion of astrocytes into the selected desired neuronal 
populations for the treatment of neurological diseases. 
In the same year (2010), Vierbuchen and colleagues 
obtained ectodermal neurons from mesodermal murine 
fibroblasts, a distantly related cell type (176) (Fig. 1). 
Starting from a pool of 19 candidate genes, by progres-
sive elimination, they identified a combination of three 
factors, achaete-scute homolog 1 (Ascl1), brain-specific 
homeobox/POU domain protein 2 (Brn2), and gene myelin 
transcription factor 1-like (Myt1l) (BAM), that suffice to 
rapidly and efficiently convert mouse embryonic and post-
natal fibroblasts into functional neurons in vitro. Ascl1 is 
a master gene in neural development that regulates neu-
ronal versus glial specification and promotes neuronal 
phenotype. Mouse embryonic fibroblasts (MEFs) from 
TauEGFP knock-in mice, which express GFP specifically 
in neurons (174,186), were infected with lentiviruses con-
taining selected genes under the control of the tetracycline 
operator (185). Fresh MEF media containing doxycycline 
was added after 16–20 h in media containing lentivirus to 
activate expression of the transduced genes. These induced 
neuronal cells (iN) expressed multiple neuron-specific 
proteins, like microtubule-associated protein 2 (MAP2) 
and β-tubulin, generated action potentials, and formed 
functional synapses, thus showing authentic neuronal 
functions. An interesting aspect was that the majority of 
obtained neuronal cells was excitatory (glutamatergic) and 
expressed markers of cortical identity. The conversion was 
rapid and efficient; after only 5 days, neuronal cells with 
long, branching processes were readily detected, and the 
efficiency ranged from 1.8% to 7.7%. The single factor 
Ascl1 was sufficient for immature neuronal feature induc-
tion, and in fact, the omission of Ascl1 had a dramatic effect 
on efficiency. To generate mature neuronal cells, the addi-
tional expression of Brn2 and Myt1l is needed (176); Brn2 
is expressed in cortical development and might play a role 
in the predominant glutamatergic phenotype observed.
Recently, the same group (128) showed that human 
fetal fibroblasts also could be directly converted into neu-
rons through an infection with the same transcription fac-
tors: Brn2, Ascl1, and Myt1l (BAM). However, the BAM 
factors induced neuronal features but did not generate 
functional neurons. Only with the addition of neural 
differentiation 1 (NeuroD1) (BAMN), another basic 
helix–loop–helix transcription factor, was the efficiency 
improved. Indeed, they obtained cells with neuronal 
morphologies, labeled positive for pan-neuronal markers 
[class III β-tubulin, neuronal nuclei (NeuN), polysialic 
acid-neural cell adhesion molecule 1 (PSA-NCAM), and 
MAP2] and with active membrane properties (128). 
In addition to the use of transcription factors, the pos-
sibility of using microRNAs (miRNAs) has recently been 
suggested for promoting the reprogramming and transdif-
ferentiation process without the use of viral vectors. Using 
miRNAs makes the generation of iPSCs more efficient 
(5), suggesting that downregulation in addition to upregu-
lation of specific genes can modulate the reprogramming.
Based on their previous studies showing that miR-9 
and miR-124 critically regulated neuronal differentiation, 
Yoo et al. recently demonstrated that their forced expres-
sion in human fibroblasts induced reprogramming into 
neurons (195). The obtained cells showed a reduction in 
proliferation and neuron-like morphologies, but only a 
low percentage (less than 5%) was MAP2 positive. To 
increase the percentage of neuronal cells, they infected 
fibroblasts with miR-9/9*-124 together with NeuroD2, 
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Ascl1, and Myt1l and found approximately 10% of the 
initially plated cells positive for MAP2 with an exten-
sive neurite outgrowth as shown by β-III tubulin staining. 
Moreover, the obtained cells could fire repetitive spe-
cific action potentials and presented glutamatergic and 
GABAergic phenotypes (195). The exploration of miR-
NAs as a tool for other transdifferentiation applications 
warrants further investigation. 
In a complementary way, transient induction of the 
four iPSC reprogramming factors (Oct4, Sox2, Klf4, 
and c-Myc) can directly differentiate murine fibro-
blasts into functional neural progenitor cells (NPCs), in 
association with specific NPC culture conditions (90). 
Compared with induced neurons, transdifferentiated 
NPCs present the advantage of being expandable in vitro 
and retaining the ability to give rise to multiple neu-
ronal subtypes and glial cells. These results point out the 
potential utility of iPSC-based reprogramming factors as 
a tool not only for full stem reprogramming but also for 
transdifferentiation.
Of interest, the transdifferentiation strategy also can 
be successfully applied to achieve specific neuronal 
populations with clinical meaning, such as the dopami- 
nergic phenotype. In fact, a combination of three transcrip-
tion factors—Mash1, nuclear receptor related 1 protein 
(Nurr1), and LIM homeobox transcription factor 1a 
(Lmx1a)—is sufficient to directly produce functional 
dopaminergic neurons from mouse and human fibro-
blasts from healthy donors and, of greater interest, from 
Parkinson’s disease patients (23). Fibroblast-derived dopa- 
minergic neurons produce dopamine and exhibit appro-
priate neurophysiological features (23). 
In a parallel and independent experiment, another 
group has obtained similar results showing that the over-
expression of the transcription factors Ascl1, Brn2, and 
Myt1l (BAM combination) with Lmx1a and forkhead 
box A2 (FoxA2), two proteins involved in dopamine 
neuron generation, can differentiate human fibroblasts 
into dopaminergic neurons (132). These dopaminergic 
neurons might be useful for in vitro disease modeling as 
well as for cell replacement therapies for the treatment of 
Parkinson’s disease. 
In the last three decades, dopaminergic cell transplan-
tation has emerged as a potentially reparative therapy for 
Parkinson’s disease (PD), given the relatively circum-
scribed nature of the neurodegenerative process involv- 
ing predominately the nigrostriatal areas. Sources for 
such cells are varied and include the developing ventral 
mesencephalon, several autologous somatic cell types, as 
well as ESCs and iPSCs (37,187). Recently successful 
engraftment of human ESC-derived dopamine neurons 
was demonstrated in animal models (using three host spe-
cies: mice, rats, and monkeys) of PD by Kriks et al. (91). 
The authors described a novel floor-plate-based strategy 
for the derivation of human dopaminergic neurons that 
efficiently engrafted in vivo, suggesting that past failures 
were due to incomplete specification rather than to a spe-
cific vulnerability of the ESCs derived cells. However, 
while pluripotent derived neurons integrated very well 
into animal models of PD after grafting, in some experi-
ments with iPSCs, they led to the formation of neural 
overgrowth because of the pluripotentiality of the start-
ing cells (29,188). The use of direct induction of somatic 
cells into dopaminergic neurons (iDAs) can circumvent 
this obstacle. In fact, the in vivo differentiation potential 
of iDA cells was assessed by orthotopic transplantations 
into neonatal mouse brains (23). Two and 6 weeks after 
transplantations, donor cells were found integrated in the 
host tissue showing an extremely elaborated morphol-
ogy and an appropriate dopaminergic phenotype. Indeed, 
it has been recently described that ectopic expression of 
defined transcription factors (11 factors selected based on 
their known functions in the development and survival of 
midbrain DA neurons) in mouse fibroblasts is sufficient 
to induce neurons with midbrain dopaminergic features. 
In addition, transplantation of these iDA cells amelio-
rated symptoms in a mouse model of PD (37). Thus, iDA 
neurons generated from abundant somatic fibroblasts by 
direct lineage reprogramming hold promise for cell-based 
therapies of PD. Further studies in PD models are needed 
to evaluate the therapeutic effect of these cells.
The direct induction of other specific neuronal sub-
types like motor neuron cells (iMNs) has recently been 
demonstrated (156). The authors investigated different 
combinations of the BAM factors with known motor neu-
ron specification factors, employing embryonic murine 
fibroblasts carrying a fluorescent reporter under the 
motor neuron-specific promoter Hb9 to track the conver-
sion to desired phenotype. They determined an optimal 
minimal combination of seven factors that generated 
a 5–10% conversion of mouse embryonic fibroblasts 
into functional active iMNs. These cells had an estab-
lished transcriptional appropriate program, exhibited the 
electrophysiological characteristics of motor neurons, 
and formed functional synapses with muscle in vitro. 
Indeed, they displayed even in vivo engraftment capac-
ity in chicken fetal spinal cord similar to ES-derived 
motor neurons. In addition, these iMNs presented both 
cell-autonomous and nonautonomous sensitivities to 
degenerative stimuli, strongly suggesting that they can be 
used as in vitro model of motor neuron disorders, like 
amyotrophic lateral sclerosis. Finally, the authors also 
successfully added NeuroD1 to their seven-factor repro-
gramming combination to reprogram human embryonic 
fibroblasts into functional, cholinergic hiMNs (156). 
Although requiring further investigation, other relevant 
neuroectodermal populations like astrocytes or oligo-
dendrocytes can be directly obtained from somatic cells 
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for basic pathogenetic studies (e.g., of nonautonomous 
events) or as cell sources for cell therapy.
Comparisons are lacking in the literature between neu-
rons derived from direct conversion and those derived 
from pluripotent cells. We know that the process of neu-
ron differentiation from pluripotent stem cells recapi- 
tulates all the steps of the developing embryonic nervous 
system and gives rise to all subtypes of neurons: spinal 
motor neurons, midbrain dopaminergic neurons, and cor-
tical neurons [for review, see (130)]. However, the ability 
to derive specific neural subtypes from induced neurons 
remains elusive, although several groups have gener-
ated dopaminergic induced neurons (23,85,132) and 
motor neuron induced neurons (156). Thus, it is crucial 
to assess the bona fide phenotype of transdifferentiated 
neurons, characterizing them both from expression pro-
files and functionality. In fact, these aspects of induced 
neurons might have potential clinical relevance when a 
specific target population is needed for cell transplan- 
tation purposes.
In spite of these considerations, induced neurons might 
have potential clinical relevance. At present, there are no 
effective treatments for diseases and injuries of the nervous 
system. The replacement of damaged cells and the restora-
tion of function are considered the ideal therapeutic strategy 
that can be addressed with reprogrammed neurons. Indeed, 
the use of differentiated neurons avoids teratoma formation, 
which can occur with embryonic stem cell transplantation. 
Moreover, terminally differentiated cells can potentially be 
used as an in vitro model to discover and test novel drugs 
and to study disease mechanisms. Furthermore, it seems 
that the direct conversion of fibroblasts into neurons can be 
more time effective—occurring, for example, as early as 
8 days (128)—in vitro than the generation of iPSCs for basic 
studies and cell therapy purposes. 
Transdifferentiation in Endodermal Derivatives: 
Hepatocytes
Under physiological conditions, liver hepatocytes 
originate from endogenous hepatic progenitor cells (199). 
However, previous experiments have demonstrated that 
the hepatocytes can also be obtained from nonhepatic 
cells after exposure to particular signals or fusion with 
hepatocytes (141,179,181). These data suggest that spe-
cific hepatocytic master genes can be activated in these 
situations. In fact, the expression of three specific com-
binations of only two transcription factors, comprising 
hepatocyte nuclear factor 4a (Hnf4α) plus Foxa1, Foxa2, 
or Foxa3, related to hepatocyte differentiation during 
liver development, is sufficient to directly differentiate 
mouse embryonic and adult fibroblasts into bona fide 
hepatocytes in vitro (145). 
In a parallel experiment, the expression of another set 
of genes—Gata4, Hnf1α, and Foxa3—and the contem-
poraneous inactivation of p19 (alternative reading frame; 
Arf) produce the direct induction of functional hepatocyte-
like (iHep) cells from mouse tail-tip fibroblasts (74). In 
both cases, the authors planned to evaluate the repro-
gramming effect of a larger pool of genes for 12 and 14 
transcription factors, respectively, progressively elimi-
nating one factor at a time until the key combination was 
found. This type of progressive approach has been used 
by Yamanaka with iPSCs (starting with 24 factors) (167) 
and also in other direct transdifferentiation approaches 
(176). Of note, in both cases, the fibroblast-derived hepa-
tocytes can reconstitute hepatic tissues in vivo in the 
livers of fumarylacetoacetate hydrolase (Fah)-deficient 
(Fah−/−) recipient mice after transplantation, even if they 
could only partially compensate liver function (74,145). 
These studies offer new insights into the molecular 
mechanisms of hepatocyte differentiation and open the 
path to novel potential therapeutic approaches for liver 
diseases (145).
Transdifferentiation In Vivo
Because promising results have been obtained in 
vitro, one goal of medicine may be to understand repro-
gramming mechanisms and take advantage of them for 
tissue repair and regeneration. To achieve this goal, an 
important step is to carry out transdifferentiation in vivo. 
In vivo cells would reside in their native environment, 
which might promote their survival and/or maturation 
and influence the reprogramming process. 
A few examples are available in the literature of in vivo 
conversion. The first is a study by Xie et al., who repro-
grammed B-cells into macrophages in vitro and then deter-
mined whether this result could also be observed in vivo 
(193). Sublethally irradiated Recombination Activating 
Gene 2 interleukin 2 γC receptor knockout (RAG2–/–gc–/–) 
mice were transplanted intravenously with B-cell precur-
sors from a bone marrow pool of CD19 ancestry mice 
infected with a C/EBPa-carrying virus. In the three ani-
mals treated, 6 days after transplantation, 51% of the C/
EBPa-expressing cells were CD19– Mac-1+ in the bone 
marrow and 32% in the spleen, markers specific to mac-
rophages. Most of the reprogrammed cells also exhibited 
relatively low side scatter values, suggesting that the in 
vivo reprogrammed cells resembled monocytes (193). 
The second in vivo study was by zhou and colleagues 
(206). Based on previous attempts to convert adult liver 
cells into β-cells in vivo by expressing pancreatic tran-
scription factors (45,83,117,179), starting from 20 tran-
scription factors and after progressive elimination, they 
identified a specific minimal combination of three tran-
scription factors, Ngn3, pancreatic and duodenal homeo-
box 1 (Pdx1), and pancreatic β-cell-specific transcriptional 
activator (MafA), that reprograms differentiated pancre-
atic exocrine cells (in adult mice) into cells that closely 
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resemble β-cells. The three selected adenoviruses were 
injected as a mixture into the splenic lobe of the dorsal 
pancreas of 2-month-old adult Rag1–/–mice. Twenty per-
cent of infected cells were converted to insulin+ cells, in 
which, by day 10, the level of insulin was comparable to 
that of endogenous β-cells (Fig. 3). Thus, the conversion 
process was rapid, requiring only few days, without cell 
division, and stable for months. Consistent with previous 
reports (180), most infected cells (95%) were found to 
be mature amylase+ exocrine cells. Most of the insulin+ 
cells coexpressed genes required for β-cell endocrine 
function, such as glucose transporter 2, glucokinase, 
prohormone convertase, and the key β-cell transcription 
factors NeuroD, gene NK2 homeobox 2 (Nkx2.2), and 
Nkx6.1. However, the induced β-cells lacked organiza-
tion into islet structures and remained as single cells or 
small clusters, probably impairing their function (206). 
Interestingly, the induced β-cells secreted insulin and 
rescued streptozotocin-induced hyperglycemia in adult 
animals, demonstrating that the reprogrammed cells pos-
sessed functional properties and that this strategy can 
have therapeutic meaning.
β-Cell destruction by immune system or their dysfunc-
tion causes diabetes mellitus type 1. A promising strategy 
of regenerative medicine is to obtain β-cells directly from 
patients’ pancreatic exocrine cells. In general, although 
limited by the obvious complications associated with in 
vivo gene delivery, in vivo reprogramming approach can 
theoretically allow an endogenous and autologous tissue 
repair without any invasive transplantation, even if this 
goal seems to be a long way off.
CONCLUSION
The lack of effective therapies for most neurodegen-
erative diseases has raised significant interest in cell-
mediated approaches as potential strategies. Cells can 
exert therapeutic action through several mechanisms, 
including cell substitution and neuroprotection. Some of 
the common degenerative diseases are potentially ame-
nable to cell therapy to replace damaged cells, tissues, 
or organs. Indeed, a primary goal of regenerative medi-
cine is to produce new cells to repair or replace diseased 
and damaged tissues. Understanding the stability and the 
possibility of altering the differentiated state of various 
cell types is interesting both from a basic biological per-
spective and for its potential to generate cells for therapy. 
Cell types obtained from somatic cells can be pluripotent 
stem cells or other differentiated somatic cells (via trans-
differentiation). These differentiated cells, such as neu-
rons or cardiomyocytes, obtained from a patient’s own 
somatic cells (from pluripotent stem cells or through 
transdifferentiation processes), would be useful in the 
regenerative medicine field because they are autologous 
and could thus theoretically preclude immunological 
rejection in cell transplantation approaches. 
The direct reprogramming of adult somatic cells into 
the desired target cells holds many possible translational 
applications. With this technology, it is now achievable to 
generate disease-specific cells that harbor the genome of 
the donor and can mimic human disease. This approach 
might allow obtaining cell lines from many different 
patients to study the nature and complexity of disease, 
comparing how the same disease varies among subjects. 
Often, translation of drug discovery from levels of cel-
lular and animal models to human therapeutics failed, 
because of the huge differences between the two systems. 
High-throughput drug screening using human transdiffer-
entiated cells based on disease models could be useful in 
filling the gap between animal models and clinical trials. 
Drug screening platforms can be developed to test com-
pounds that are able to revert disease-related phenotype 
to that of the control. It would be possible to perform a 
personalized toxicological risk assessment as well as to 
evaluate the response to specific drugs in cells with iden-
tical genetic blueprint of the individuals from which they 
are generated. 
Figure 3. Direct in vivo reprogramming. Schematic experimental design of in vivo transdifferentiation: injection of the transcription 
factors neurogenin 3 (Ngn3), pancreatic and duodenal homeobox 1 (Pdx1), and pancreatic β-cell-specific transcriptional activator 
(MafA) intravenously induces pancreatic exocrine cells to convert into β-cells (206).
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Moreover, transdifferentiation could be an innovative 
way of achieving the goal of regenerative medicine, con-
sidering that existing adult cells may be converted directly 
into other medically important cell types to repair diseased 
or damaged tissues. Indeed, the final product of transdif-
ferentiation would be readily useful for direct clinical 
application because of their full commitment, whereas 
ESCs and iPSCs must be converted into mature or pro-
genitor cells through various steps of differentiation. One 
major weakness of pluripotent stem cells is that they can 
generate tumorigenic cells in vivo, while transdifferenti-
ated somatic cells would overcome this issue. The gen-
eration of iPSCs is still a lengthy and inefficient process, 
as is the generation of specific differentiated phenotypes 
from iPSCs, which is a multiphasic procedure requiring 
several chronologically regulated molecular signals and 
often producing mixed populations.
In theory, eliminating the pluripotent stem cell stage 
probably avoids the risk of tumorigenesis when the cells 
are transplanted. On the other hand, the absolute absence 
of replication, as in the case of direct differentiation of 
somatic cells into neurons, might generate a problem in 
terms of the number of cells available for transplantation. 
It is likely that for clinical application, the amount of donor 
cells requested for transplantation will be huge and not eas-
ily satisfied by the direct generation procedure. In fact, the 
efficiency of direct reprogramming is generally not very 
high—less than ~5% on average among the studies describ-
ing fibroblast-to-neuron conversion. Yoo et al. reported 
that the efficiency was even further diminished when start-
ing from adult human cells, while neuronal maturation was 
delayed as well (195). Indeed, the age of the donor and the 
number of cell passages for starting cells like fibroblasts 
can influence the success of the transdifferentiation. 
Another consideration is how long the cells originat-
ing from transdifferentiation can be maintained in culture 
and if they are too fragile or susceptible to stress to be 
cultured in the long term and then used for cell trans-
plantation. Thus, it is necessary that reprogramming 
techniques be further developed to allow for the robust 
and efficient generation of target desired cells for prac-
tical application. In fact, although the number of cells 
obtained up to now with direct differentiation can be suf-
ficient for in vitro basic studies, it might not represent a 
sufficient amount of cells for in vivo cell transplantation 
purposes. At present, it is not clear if the potential for 
beneficial results from the transplantations would arise 
more from partially differentiated or fully differentiated 
cells and have added relevant text. In the field of neuro-
degenerative diseases, the use of neural stem cells as an 
alternative to already differentiated neurons can apply for 
different purposes. For example, it might be possible to 
replace lost neurons or glial cells by transplantation of 
stem cell-derived cells that have been predifferentiated 
in vitro to various stages of maturation, for example, into 
neuroblasts (i.e., immature neurons). On the other hand, 
transplanted neural stem cells can be more effective in 
producing functional improvement by releasing thera-
peutic molecules that are neuroprotective.
Direct converted cell transplantation has yet to be 
experimentally tested in most organ systems, even if 
some experimental demonstration has been provided. 
For example, transplanted fibroblast-derived hepatocytes 
repopulated the livers of fumarylacetoacetate-hydrolase-
deficient (Fah–/–) mice and rescued half of recipients 
from death by restoring liver function (74). Regarding 
the cardiovascular system, it has been described that 
fibroblasts induced into cardiac cells further completed 
their cardiac differentiation in vivo in immunosuppressed 
NOD-SCID mouse hearts, with interesting implication 
for the development of repair strategy for cardiac dis-
eases (77). A remarkable example of autologous cell 
replacement therapies was provided by using multipotent 
blood progenitors obtained from fibroblasts through the 
forced overexpression of OCT4 (164). Reprogrammed 
hematopoietic cells engrafted and repopulated bone mar-
row in all transplanted recipient animals at 20% level 
(164). This represents a proof of principle that converting 
fibroblasts or other patient specific cells into hematopoi-
etic cells may be a source for autologous transplantation. 
Indeed, it has been recently demonstrated the possibi- 
lity of using fibroblast-derived neuron cells as a source of 
transplantable cells with therapeutic regenerative poten-
tial in PD model (37). However, only one functional 
test was used to evaluate the disease improvement, too 
limited with respect to the complete investigation of PD 
phenotype that is required in preclinical trials. Indeed, 
the number of effective induced cells required is greater 
than that required with neuronal precursors derived from 
CNS. Overall, it seems that directly differentiated neu-
rons, generated with the available methods, are only 
partially therapeutic effective with respect to those gener-
ated from pluripotent stem cells or derived from tissues-
specific precursors. A direct comparison is still lacking. 
Further studies are needed for the effective development 
of this strategy. Regardless, transdifferentiated cells must 
be widely characterized before use in the clinic. The first 
step to determine the identity of the cell type produced 
and to ensure that they do not express markers of the ini-
tial cell type is evaluation of marker genes by immuno-
cytochemistry and gene expression analysis. Analysis 
of cellular morphology can provide further information 
about the successful generation of a particular cell type. 
Furthermore, physiological behaviors can be tested to 
establish whether the cells display functional proper-
ties that are similar to those of the same type in vivo. It 
can also be important to evaluate the transcription pro-
file, DNA methylation, and histone modifications of the 
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differentiated cells relative to their in vivo correlated tis-
sue (32). Indeed, it is necessary to determine the fidelity 
of reprogramming and define a clinically acceptable level 
of genomic integrity for transdifferentiated cells. Multiple 
kinds of genomic changes have been observed in human 
iPSCs (109), and chromosomal aneuploidy and translo-
cations, megabase-scale duplications/deletions, and point 
mutations have all been described (52,76,100,109,110). 
Moreover, the reprogramming process may cause epig-
enomic reorganization, DNA methylation alteration, and 
histone modifications. As in the case of iPSCs, these 
events may occur during the reprogramming process for 
the cell transdifferentiation. Up to now, no specific stud-
ies have analyzed this aspect in transdifferentiated cells.
Most current methods of producing transdifferentiated 
cells involve viral gene delivery that could cause abnor-
malities in the induced cells. Random integration of the 
reprogramming genes may result in insertional mutagen-
esis that causes malignant transformation of a clonal cell 
population. Research should focus on producing induced 
cells without using viral vectors as with iPSCs, such as 
applying nonintegrating viral (161), nonviral episomal 
(123,196), and excisional (82,191) techniques for repro-
gramming, or treatment with small molecules (75,205), 
cell signaling peptides [e.g., wingless-type MMTV inte-
gration site family (Wnt)] (107), or microRNAs (163). 
Moreover, coculture with animal cells or animal media 
could lead to immune reactions against animal proteins 
in the cells and infection caused by animal microbes. 
Using animal substance-free culture media, feeder cells, 
or a feeder-free matrix in derivation, passaging, expan-
sion, and cryopreservation procedures can avoid these 
problems and produce clinical-grade cells with Good 
Manufacturing Practice (GMP) quality.
Distinct cell types are defined by their unique combi-
nation of epigenetic marks that are accumulated progres-
sively during numerous developmental steps. Thus, other 
crucial points to deal with are the epigenetic features of 
the obtained cells. Changes in transcriptional activity 
could lead to genome-wide modifications such as DNA 
methylation, histone adjustments, and alteration of chro-
matin remodeling complexes (79,207). In light of this 
information, a potential benefit of transdifferentiation 
approaches is that only some of the numerous epigenetic 
markers established during development need to be rear-
ranged, so this process requires fewer proliferation steps 
and may reduce mutation events. Meanwhile, iPSC gen-
eration removes several epigenetic markers that must be 
reestablished during the in vitro differentiation process. 
These changes could result in unstable phenotypes when 
cells are transplanted in vivo (207).
Another promising advantage of the transdifferentia-
tion process is the possibility of inducing the desired cell 
types directly in vivo for in situ regeneration and repair 
(55). Indeed, the in vivo model can provide an appropriate 
three-dimensional setting, as it has been shown that differ-
entiated human cells mature more properly if transplanted 
into an adult mouse than when cultured only in vitro (92); 
therefore, it may be advantageous to induce transdiffer-
entiation directly in the native tissue. Transdifferentiation 
thus represents an attractive approach that may become 
an important feature of regenerative medicine. However, 
other studies regarding safe delivery of defined factors 
and development of current protocols in preclinical model 
systems are required to improve this technology for poten-
tial application in preclinical and clinical studies.
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